



PB 32 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 March 2024

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023</i>	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 April 2024	3
<i>National Health (Minimum Stockholding) Determination 2023</i>	3

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024*.
- (2) This instrument may also be cited as PB 32 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 April 2024.	1 April 2024
2. Schedule 1	Immediately after the commencement of Schedule 3 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023</i> .	1 April 2024
3. Schedule 2	1 April 2024.	1 April 2024

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023*

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Pregabalin	Omit: Capsule 150 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
------------	-------------------------	------	------------------	---

2 Schedule 1 (table)

Pregabalin	Omit: Capsule 75 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
------------	------------------------	------	------------------	---

Schedule 2—Amendments commencing 1 April 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Before:

Aripiprazole	Tablet 10 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
--------------	--------------	------	------------------	---

insert:

Anastrozole	Tablet 1 mg	Oral	Arimidex	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
-------------	-------------	------	----------	--

2 Schedule 1 (table)

After:

Bosentan	Tablet 125 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
----------	--------------------------------	------	----------------	--

insert:

Bosentan	Tablet 125 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
----------	--------------------------------	------	----------	--

Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
----------	---------------------------------	------	----------	--

3 Schedule 1 (table)

After:

Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral	Cal-500	after 30 November 2023—6 months stock by reference to usual PBS demand
---------	---	------	---------	--

insert:

Candesartan	Tablet containing candesartan cilexetil 16 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
-------------	---	------	--------------------	---

Candesartan	Tablet containing candesartan cilexetil 32 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by
-------------	---	------	--------------------	---

				reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand

4 Schedule 1 (table)

After:

Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	4 months stock by reference to usual PBS demand
	insert:			
Clindamycin	Capsule 150 mg (as hydrochloride)	Oral	Clindamycin BNM	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand

5 Schedule 1 (table)

Omit:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	Fenac	between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand
------------	--	------	-------	--

6 Schedule 1 (table)

Omit:

Domperidone	Tablet 10 mg	Oral	Motilium	between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand
-------------	--------------	------	----------	---

7 Schedule 1 (table)

Omit:

Folinic acid	Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL	Injection	Leucovorin Calcium (Pfizer Australia Pty Ltd)	between 1 March 2024 and 31 July 2024—0 months stock by reference to usual demand
--------------	--	-----------	---	---

8 Schedule 1 (table)

Omit:

Glimepiride	Tablet 1 mg	Oral	Aylide 1	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand
Glimepiride	Tablet 2 mg	Oral	Aylide 2	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand
Glimepiride	Tablet 3 mg	Oral	Aylide 3	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand
Glimepiride	Tablet 4 mg	Oral	Aylide 4	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand

9 Schedule 1 (table)

Omit:

Hydralazine	Tablet containing hydralazine hydrochloride 25 mg	Oral	Alphapress 25	between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand
-------------	---	------	---------------	---

10 Schedule 1 (table)

Omit:

Macrogol 3350	Powder for oral solution 510 g	Oral	OsmoLax	between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand
---------------	--------------------------------	------	---------	---

11 Schedule 1 (table)

After:

Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Penthrox	6 months stock by reference to usual PBS demand
----------------	---	---------------------	----------	---

insert:

Methylprednisolone	Injection containing methylprednisolone acetate 40 mg in 1 mL	Injection	Depo-Nisolone	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
--------------------	--	-----------	---------------	--

12 Schedule 1 (table)

Omit:

Methylprednisolone	Powder for injection 40 mg (as sodium succinate)	Injection	Methylpred	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
--------------------	--	-----------	------------	---

13 Schedule 1 (table)

After:

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
-------------------	--	------	----------	--

insert:

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	Noumed Mycophenolate	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
-------------------	--	------	-------------------------	---

14 Schedule 1 (table)

Omit:

Oxybutynin	Tablet containing oxybutynin hydrochloride 5 mg	Oral	Ditropan	between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand
------------	---	------	----------	---

15 Schedule 1 (table)

Before:

Pregabalin	Capsule 150 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
------------	----------------	------	----------	--

insert:

Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	NOUMED PIOGLITAZONE	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	Pioglitazone Sandoz	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	NOUMED PIOGLITAZONE	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	Pioglitazone Sandoz	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand

16 Schedule 1 (table)

Omit:

Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, 15 mL	Application to the Eye	Systane	between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand
---	-----------------------------------	------------------------	---------	---

17 Schedule 1 (table)

Omit:

Pregabalin	Capsule 25 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
------------	---------------	------	------------------	---

18 Schedule 1 (table)

Omit:

Pregabalin	Capsule 300 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
------------	----------------	------	------------------	---

19 Schedule 1 (table)

Omit:

Prochlorperazine	Tablet containing prochlorperazine maleate 5 mg	Oral	Stemzine	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
------------------	---	------	----------	---

20 Schedule 1 (table)

After:

Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	Oral	Triasyn 2.5/2.5	4 months stock by reference to usual PBS demand
--------------------------	---	------	-----------------	---

insert:

Riluzole	Oral suspension 50 mg per 10 mL, 300 mL	Oral	Teglutik	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
----------	---	------	----------	--

21 Schedule 1 (table)

Omit:

Risperidone	Tablet 1 mg	Oral	Risperidone generichealth	between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand
-------------	-------------	------	---------------------------	---

Risperidone	Tablet 2 mg	Oral	Risperidone generichealth	between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand
-------------	-------------	------	---------------------------	---

22 Schedule 1 (table)

Omit:

Risperidone	Tablet 3 mg	Oral	Risperidone generichealth	between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand
-------------	-------------	------	---------------------------	---

23 Schedule 1 (table)

After:

Risperidone	Tablet 4 mg	Oral	Risperidone generichealth	between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand
-------------	-------------	------	------------------------------	---

insert:

Rosuvastatin	Tablet 10 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand

24 Schedule 1 (table)

Omit:

Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	Rectal	Micolette	between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand
--	---	--------	-----------	---

25 Schedule 1 (table)

After:

Thiamine	Tablet containing thiamine hydrochloride 100 mg	Oral	Betavit	4 months stock by reference to usual PBS demand
----------	--	------	---------	---

insert:

Tobramycin	Injection 80 mg (as sulfate) in 2 mL (without preservative)	Injection	Pfizer Australia Pty Ltd	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
------------	--	-----------	-----------------------------	--

26 Schedule 1 (table)

	After:				
Topiramate	Tablet 100 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand	
	insert:				
Topiramate	Tablet 100 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand	

27 Schedule 1 (table)

	After:			
Topiramate	Tablet 200 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
	insert:			
Topiramate	Tablet 200 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand

28 Schedule 1 (table)

	After:			
Topiramate	Tablet 25 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
	insert:			
Topiramate	Tablet 25 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand

29 Schedule 1 (table)

	After:			
Topiramate	Tablet 50 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
	insert:			
Topiramate	Tablet 50 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand

30 Schedule 1 (table)

Omit:

Tropisetron	I.V. injection 5 mg (as hydrochloride) in 5 mL	Injection	Tropisetron-AFT	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
-------------	--	-----------	-----------------	---

31 Schedule 1 (table)

After:

Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatris	after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together
--------------	---------------	------	----------------------	--

insert:

Valaciclovir	Tablet 500 mg (as hydrochloride)	Oral	NOUMED VALACICLOVIR	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
--------------	----------------------------------	------	---------------------	--

32 Schedule 1 (table)

Omit:

Vinorelbine	Solution for I.V. infusion 10 mg (as tartrate) in 1 mL	Injection	Navelbine	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand
-------------	--	-----------	-----------	--

33 Schedule 1 (table)

Omit:

Voriconazole	Tablet 200 mg	Oral	Vfend	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
--------------	---------------	------	-------	---